{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Tvardi Therapeutics, Inc.
Is Tvardi Therapeutics, Inc. overvalued or undervalued?
As of March 1, 2022, Tvardi Therapeutics, Inc. is considered a risky investment due to its overvaluation indicated by a negative P/E ratio of -9.66 and EV/EBITDA of -10.10, despite a recent 1-year return of 276.26%, which is overshadowed by a long-term decline of 92.59% over the past five years.
Tvardi Therapeutics Hits New 52-Week High at $40.77
Tvardi Therapeutics, Inc. has achieved a new 52-week high of USD 40.77, significantly up from its low of USD 8.13. With a market capitalization of USD 278 million and a unique capital structure, the company has shown a 17.14% performance relative to the S&P 500 over the past year.
Tvardi Therapeutics Hits New 52-Week High at $39.04
Tvardi Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 278 million, the company has a price-to-book ratio of 8.45 and a negative debt-to-equity ratio. It has outperformed the S&P 500 over the past year.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
